Shadi Yaghi1, Amelia K Boehme2, Jamil Dibu3, Christopher R Leon Guerrero4, Syed Ali5, Sheryl Martin-Schild6, Kara A Sands7, Ali Reza Noorian8, Christina A Blum9, Shuchi Chaudhary10, Lee H Schwamm11, David S Liebeskind8, Randolph S Marshall2, Joshua Z Willey2. 1. Department of Neurology, Columbia University Medical Center, New York, New York2currently with the Department of Neurology, Brown University, Providence, Rhode Island. 2. Department of Neurology, Columbia University Medical Center, New York, New York. 3. Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio. 4. Department of Neurology, Washington University in St Louis, St Louis, Missouri. 5. Department of Neurology, University of Arkansas for Medical Sciences, Fayetteville. 6. Department of Neurology, Tulane University, New Orleans, Louisiana. 7. Department of Neurology, The University of Alabama at Birmingham, Birmingham. 8. Department of Neurology, UCLA (University of California, Los Angeles), for the UCLA Acute Stroke Investigators, Los Angeles. 9. Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia. 10. Department of Neurology, University of Oklahoma, Norman. 11. Department of Neurology, Massachusetts General Hospital, Boston.
Abstract
IMPORTANCE: Treatments for symptomatic intracerebral hemorrhage (sICH) are based on expert opinion, with limited data available on efficacy. OBJECTIVE: To better understand the natural history of thrombolysis-related sICH, with a focus on the efficacy of various treatments used. DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective study between January 1, 2009, and April 30, 2014, at 10 primary and comprehensive stroke centers across the United States. Participants were all patients with sICH, using the definition by the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), which included a parenchymal hematoma type 2 and at least a 4-point increase in the National Institutes of Health Stroke Scale score. MAIN OUTCOMES AND MEASURES: The primary outcome was in-hospital mortality, and the secondary outcome was hematoma expansion, defined as a 33% increase in the hematoma volume on follow-up imaging. RESULTS: Of 3894 patients treated with intravenous recombinant tissue plasminogen activator (rtPA) within 4½ hours after symptom onset of ischemic stroke, 128 (3.3%) had sICH. The median time from initiation of rtPA therapy to sICH diagnosis was 470 minutes (range, 30-2572 minutes), and the median time from diagnosis to treatment of sICH was 112 minutes (range, 12-628 minutes). The in-hospital mortality rate was 52.3% (67 of 128), and 26.8% (22 of 82) had hematoma expansion. In the multivariable models, code status change to comfort measures after sICH diagnosis was the sole factor associated with increased in-hospital mortality (odds ratio, 3.6; 95% CI, 1.2-10.6). Severe hypofibrinogenemia (fibrinogen level, <150 mg/dL) was associated with hematoma expansion, occurring in 36.3% (8 of 22) of patients without hematoma expansion vs in 25.0% (15 of 60) of patients with hematoma expansion (P = .01), highlighting a role for cryoprecipitate in reversing rtPA coagulopathy. CONCLUSIONS AND RELEVANCE: In this study, treatment of postthrombolysis sICH did not significantly reduce the likelihood of in-hospital mortality or hematoma expansion. Shortening the time to diagnosis and treatment may be a key variable in improving outcomes of patients with sICH.
IMPORTANCE: Treatments for symptomatic intracerebral hemorrhage (sICH) are based on expert opinion, with limited data available on efficacy. OBJECTIVE: To better understand the natural history of thrombolysis-related sICH, with a focus on the efficacy of various treatments used. DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective study between January 1, 2009, and April 30, 2014, at 10 primary and comprehensive stroke centers across the United States. Participants were all patients with sICH, using the definition by the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), which included a parenchymal hematoma type 2 and at least a 4-point increase in the National Institutes of Health Stroke Scale score. MAIN OUTCOMES AND MEASURES: The primary outcome was in-hospital mortality, and the secondary outcome was hematoma expansion, defined as a 33% increase in the hematoma volume on follow-up imaging. RESULTS: Of 3894 patients treated with intravenous recombinant tissue plasminogen activator (rtPA) within 4½ hours after symptom onset of ischemic stroke, 128 (3.3%) had sICH. The median time from initiation of rtPA therapy to sICH diagnosis was 470 minutes (range, 30-2572 minutes), and the median time from diagnosis to treatment of sICH was 112 minutes (range, 12-628 minutes). The in-hospital mortality rate was 52.3% (67 of 128), and 26.8% (22 of 82) had hematoma expansion. In the multivariable models, code status change to comfort measures after sICH diagnosis was the sole factor associated with increased in-hospital mortality (odds ratio, 3.6; 95% CI, 1.2-10.6). Severe hypofibrinogenemia (fibrinogen level, <150 mg/dL) was associated with hematoma expansion, occurring in 36.3% (8 of 22) of patients without hematoma expansion vs in 25.0% (15 of 60) of patients with hematoma expansion (P = .01), highlighting a role for cryoprecipitate in reversing rtPA coagulopathy. CONCLUSIONS AND RELEVANCE: In this study, treatment of postthrombolysis sICH did not significantly reduce the likelihood of in-hospital mortality or hematoma expansion. Shortening the time to diagnosis and treatment may be a key variable in improving outcomes of patients with sICH.
Authors: Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren Journal: Lancet Date: 2007-01-27 Impact factor: 79.321
Authors: J Claude Hemphill; Steven M Greenberg; Craig S Anderson; Kyra Becker; Bernard R Bendok; Mary Cushman; Gordon L Fung; Joshua N Goldstein; R Loch Macdonald; Pamela H Mitchell; Phillip A Scott; Magdy H Selim; Daniel Woo Journal: Stroke Date: 2015-05-28 Impact factor: 7.914
Authors: K W Mahaffey; C B Granger; M A Sloan; C L Green; J M Gore; W D Weaver; H D White; M L Simoons; G I Barbash; E J Topol; R M Califf Journal: Am Heart J Date: 1999-09 Impact factor: 4.749
Authors: Joji B Kuramatsu; Stefan T Gerner; Peter D Schellinger; Jörg Glahn; Matthias Endres; Jan Sobesky; Julia Flechsenhar; Hermann Neugebauer; Eric Jüttler; Armin Grau; Frederick Palm; Joachim Röther; Peter Michels; Gerhard F Hamann; Joachim Hüwel; Georg Hagemann; Beatrice Barber; Christoph Terborg; Frank Trostdorf; Hansjörg Bäzner; Aletta Roth; Johannes Wöhrle; Moritz Keller; Michael Schwarz; Gernot Reimann; Jens Volkmann; Wolfgang Müllges; Peter Kraft; Joseph Classen; Carsten Hobohm; Markus Horn; Angelika Milewski; Heinz Reichmann; Hauke Schneider; Eik Schimmel; Gereon R Fink; Christian Dohmen; Henning Stetefeld; Otto Witte; Albrecht Günther; Tobias Neumann-Haefelin; Andras E Racs; Martin Nueckel; Frank Erbguth; Stephan P Kloska; Arnd Dörfler; Martin Köhrmann; Stefan Schwab; Hagen B Huttner Journal: JAMA Date: 2015-02-24 Impact factor: 56.272
Authors: Brett Cucchiara; David Tanne; Steven R Levine; Andrew M Demchuk; Scott Kasner Journal: J Stroke Cerebrovasc Dis Date: 2008 Nov-Dec Impact factor: 2.136
Authors: Craig S Anderson; Yining Huang; Ji Guang Wang; Hisatomi Arima; Bruce Neal; Bin Peng; Emma Heeley; Christian Skulina; Mark W Parsons; Jong Sung Kim; Qing Ling Tao; Yue Chun Li; Jian Dong Jiang; Li Wen Tai; Jin Li Zhang; En Xu; Yan Cheng; Stephane Heritier; Lewis B Morgenstern; John Chalmers Journal: Lancet Neurol Date: 2008-04-07 Impact factor: 44.182
Authors: Joshua A Stone; Joshua Z Willey; Salah Keyrouz; James Butera; Ryan A McTaggart; Shawna Cutting; Brian Silver; Bradford Thompson; Karen L Furie; Shadi Yaghi Journal: Curr Treat Options Neurol Date: 2017-01 Impact factor: 3.598
Authors: Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss Journal: Neurocrit Care Date: 2016-02 Impact factor: 3.210
Authors: Jason Siegel; Michael A Pizzi; J Brent Peel; David Alejos; Nnenne Mbabuike; Benjamin L Brown; David Hodge; W David Freeman Journal: Curr Cardiol Rep Date: 2017-08 Impact factor: 2.931
Authors: Ahmed K Pasha; Muhammad Umer Siddiqui; Muhammad Danial Siddiqui; Adnan Ahmed; Ammar Abdullah; Irbaz Riaz; M Hassan Murad; Haraldur Bjarnason; Waldemar E Wysokinski; Robert D McBane Journal: J Thromb Thrombolysis Date: 2021-08-31 Impact factor: 2.300
Authors: Matthew T Bender; Thomas K Mattingly; Redi Rahmani; Diana Proper; Walter A Burnett; Jason L Burgett; Joshua LEsperance; Jeremy T Cushman; Webster H Pilcher; Curtis G Benesch; Adam G Kelly; Tarun Bhalla Journal: Stroke Vasc Neurol Date: 2021-12-24